Table 1.
Baseline clinical, virological, and histological features of sixty-two HCV patients and comparison of these features between responder and nonresponder patients to treatment.
| Characteristics | HCV patients | Responders | Nonresponders | P value |
|---|---|---|---|---|
| N = 62 | N = 41 (66.1%) | N = 21 (33.9%) | ||
| Male/female | 51/11 | 34/7 | 17/4 | 1.000 |
| Age (mean ± S.E) | 40.53 ± 1.17 | 39.44 ± 1.5 | 42.67 ± 1.67 | 0.160 |
| Liver function | ||||
| ALT (IU/L) | ||||
| (mean ± S.E) | 73.9 ± 4.5 | 67.93 ± 5 | 85.62 ± 8 | 0.041 # |
| AST (IU/L) | ||||
| (mean ± S.E) | 61.6 ± 4.9 | 61.44 ± 7.13 | 61.9 ± 4.5 | 0.956 |
| AFP (U/L) | ||||
| (mean ± S.E) | 7.1 ± 1.5 | 6.7 ± 2.1 | 7.78 ± 1.6 | 0.692 |
| HCV-RNA level | ||||
| Low | 20 (32.3%) | 12 (29.3%) | 8 (38.1%) | 0.035 # |
| Moderate | 27 (43.5%) | 21 (51.2%) | 6 (28.6%) | |
| High | 5 (8.1%) | 2 (4.9%) | 3 (14.3%) | |
| Unknown | 10 (16.1%) | 6 (14.6%) | 6 (28.6%) | |
| Activity score | ||||
| A1 | 49 (79%) | 35 (85.4%) | 14 (66.7%) | 0.044 # |
| A2 | 13 (21%) | 6 (14.6%) | 7 (33.3%) | |
| Fibrosis score | ||||
| F1 | 28 (45.2%) | 21 (51.2%) | 7 (33.3%) | 0.05 # |
| F2 | 20 (32.3%) | 14 (34.1%) | 6 (28.6%) | |
| F3 | 14 (22.6%) | 6 (14.6%) | 8 (38.1%) |
# Significant difference at P ≤ 0.05; between responder and nonresponder patients to treatment. No patients had A0 or A3 activity and F0 or F4 fibrosis.